An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. Outline of the protocol. Oral Contraceptive and Hemostasis Study Group.
Complementary to the epidemiological knowledge on the association between oral contraceptive use and the occurrence of venous thromboembolism, a study was designed to obtain more conclusive data regarding the effect of estrogen dose and progestogen type of oral contraceptives on risk markers for the occurrence of venous thromboembolism. The protocol for this multicenter, randomized, open label, parallel group, comparative study is outlined in the present article. A total of 730 healthy, nonsmoking, mulliparous women were treated for six cycles with one of the seven monophasic oral contraceptives tested in this study. The effects of progestogen type (desogestrel, gestodene, levonorgestrel, and norgestimate) and the effects of ethinyl estradiol dose (50, 30, and 20 micrograms) on various hemostatic variables was assessed, including the key components of the anticoagulant and fibrinolytic system, as well as the coagulation system. The primary outcome variables in the study were prothrombin fragment 1 + 2 and D-dimer.
D001777:Blood Coagulation / Q000187:drug effects; D003276:Contraceptives, Oral / Q000009:adverse effects*; D017135:Desogestrel / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D016912:Levonorgestrel / Q000009:adverse effects; D009644:Norgestrel / Q000009:adverse effects / Q000031:analogs & derivatives; D009652:Norpregnenes / Q000009:adverse effects; D010446:Peptide Fragments / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism; D020246:Venous Thrombosis / Q000139:chemically induced
D003276:Contraceptives, Oral; D005338:Fibrin Fibrinogen Degradation Products; D009652:Norpregnenes; D010446:Peptide Fragments; C036309:fibrin fragment D; C045879:prothrombin fragment 1.2; C033273:Gestodene; D009644:Norgestrel; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D017135:Desogestrel; D011516:Prothrombin; C017576:norgestimate; D013917:Thrombin